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Approximately 1 million people in the United States and over 30 million worldwide 
are living with human immunodeﬁ  ciency virus type 1 (HIV-1). While mortality from 
untreated infection approaches 100%, survival improves markedly with use of con-
temporary antiretroviral therapies (ART). In the United States, 25 drugs are approved 
for treating HIV-1, and increasing numbers are available in resource-limited countries. 
Safe and effective ART is a cornerstone in the global struggle against the acquired 
immunodeﬁ  ciency syndrome. Variable responses to ART are due at least in part to 
human genetic variants that affect drug metabolism, drug disposition, and off-site 
drug targets. Deﬁ  ning effects of human genetic variants on HIV treatment toxicity, 
efﬁ  cacy, and pharmacokinetics has far-reaching implications. In 2010, the National 
Institute of Allergy and Infectious Diseases sponsored a workshop entitled, Pharma-
cogenomics – A Path Towards Personalized HIV Care. This article summarizes work-
shop objectives, presentations, discussions, and recommendations derived from this 
meeting. Key words: HIV therapy, pharmacogenetics, pharmacogenomics, workshop
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A
ccess to antiretroviral therapy (ART) is 
a cornerstone in the fight against 
AIDS.1 Interindividual variability in ART 
pharmacokinetics, efﬁ   cacy, and toxicity may be 
affected by genetic variants relevant to drug metab-
olism, disposition, and off-site targets.2 In June 
2010, the National Institute of Allergy and Infec-
tious Diseases (NIAID) sponsored a workshop 
entitled, Pharmacogenomics – A Path Towards 
Personalized HIV Care. The impetus was the con-
viction that knowledge of associations between 
human genetics and HIV treatment responses can 
beneﬁ   t individuals and populations worldwide. 
This document summarizes the workshop and 
resultant recommendations.
*See the Acknowledgments for a complete list of participants.that efavirenz should be avoided in individuals of 
African descent. This highlights the potential harm 
resulting from the uninformed use of genetic infor-
mation. Multiple genetic variants are also associ-
ated with nevirapine toxicities.14–17
Regarding strategies to ﬁ  nd new associations, 
Amalio Telenti considered 3 aspects of pharma-
cogenomic discovery: (1) intermediate versus 
clinical phenotypes; (2) genetic and genomic 
approaches; and (3) discovery, replication, and 
functional validation. There are many functional 
variants of potential importance in ADME genes, 
but for most antiretrovirals little is known about 
effects of genetic variants on toxicity, efﬁ  cacy, 
and pharmacokinetics. To demonstrate that phe-
notypes with outliers are good endpoints, he 
described the skewed population distribution of 
lopinavir pharmacokinetics and the discovery of a 
possibly causative variant in SLCO1B1.18,19 Multiple 
loss-of-function variants along an ADME pathway 
may more profoundly affect pharmacokinetics.20 
Genomic discoveries in the general population 
should be translated into the HIV ﬁ  eld, including 
markers of metabolic complications.21,22
Regarding issues in validation, Marylyn Ritchie 
discussed statistical issues in genomic associa-
tion studies. Without very large studies, genome-
wide association studies (GWAS) may miss true 
associations when using thresholds derived from 
Bonferroni correction (eg, P < 5x10-8 for genome-
wide signiﬁ  cance), but accruing sufﬁ  ciently large 
studies is not always feasible. Alternatives include 
the false discovery rate, permutation testing, and 
relaxed  P-value thresholds, emphasizing effect 
sizes and independent replication. It is unclear 
The workshop assembled individuals with com-
plementary expertise to exchange ideas relevant 
to HIV pharmacogenomics and to develop recom-
mendations for advancing the ﬁ  eld. The ﬁ  rst day 
included presentations by invited speakers, with 
intervening panel discussions. Participants were 
then assigned to working groups – Accelerating 
Pharmacogenomic Research, The Path from Bench 
to Beside, and Pharmacogenomics and Clinical Tri-
als – and were charged with drafting recommenda-
tions. Participants reconvened on the second day to 
review recommendations.
HUMAN GENETIC PREDICTORS IN HIV 
TREATMENT
Current HIV pharmacogenomic knowledge was 
reviewed by David Haas. Orally administered 
antiretrovirals undergo absorption, distribution, 
metabolism, and elimination (ADME), and many 
ADME genes have functional variants. Non-
ADME genes can also affect treatment responses. 
Table 1 lists well-established associations between 
genetics and antiretrovirals. Regarding HLA-
B*5701 screening for abacavir hypersensitivity,3–6 
guidelines recommend that test positivity be docu-
mented as abacavir allergy in the medical record,7 
but even such a beneﬁ  cial test took many years to 
reach practice. Regarding the relevance of CYP2B6 
variants for efavirenz,8–13 population differences in 
genotype frequency largely explain higher plasma 
efavirenz exposure among populations of African 
ancestry. This together with an association between 
CYP2B6 and central nervous system (CNS) adverse 
experiences8 led some clinicians to incorrectly infer 
Drug Genotype Phenotype References
Abacavir HLA-B*5701 Hypersensitivity reaction 3–6
Atazanavir, indinavir UGT1A1*28 Hyperbilirubinemia 25–27
Efavirenz CYP2B6 516G→T, 983T→C, 
others
Increased plasma concentration 8–13
Lopinavir SLCO1B1 521T→C Increased plasma concentration 18, 19, 28
Nelﬁ  navir CYP2C19 681G→A Increased plasma concentration 10, 29
Nevirapine CYP2B6 516G→T Increased plasma concentration 9, 30–32
Nevirapine HLA-B*3505, -Cw*04, -DR*0101 Hypersensitivity reaction 14–17
Protease inhibitors APOC, others Dyslipidemia 21, 33, 34
Table 1.  Well-established genetic associations for antiretroviral drugs
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pharmacogenetic dosing. Initial studies identiﬁ  ed 
an association between CYP2C9*2, *3 and warfarin 
metabolism, which spurred trials of CYP2C9 geno-
type-based dosing. Initial studies were not highly 
successful, in part due to reliance on a single gene. 
Subsequent collaborations demonstrated that to 
accurately estimate warfarin dose, dosing equa-
tions should include at least 2 genes (VKORC1 and 
CYP2C9) and clinical factors (eg, age, body surface 
area). This work fostered www.WarfarinDosing.
org, a National Institutes of Health (NIH)–sup-
ported site that incorporates genetic and nonge-
netic factors to guide dosing.
Regarding resource-limited settings, Gary 
Maartens reminded participants that human 
genetic diversity is greatest in Africa and that 
Africa also has the greatest HIV burden. Popula-
tion genetic structure must be considered when 
assessing genetic tests. For example, while HLA-
B*5701 testing is routine in many countries, this 
variant is rare in native Africans. It was once 
argued that CD4 cell testing was not feasible in 
Africa, but it is now available based on its clini-
cal importance and cost-effectiveness. Increased 
research in Africa will likely identify novel and 
relevant genetic associations. Furthermore, knowl-
edge of population frequencies of relevant vari-
ants may inform policy.
The power of informatics to improve patient 
care was discussed by Dan Masys. He recounted 
how, at one major US medical center, implementa-
tion of computerized provider order entry (CPOE) 
markedly reduced medication prescribing errors. 
Human genomics is the current archetype for 
health care complexity. Because handling such 
complex data exceeds the ability of any practitio-
ner, computerized clinical decision support and 
electronic medical records will be critical. Genom-
ics dramatically increases data complexity, but fail-
ure to use such data will lead to suboptimal patient 
care. Broadly adopting electronic medical records 
may help solve this problem.
STRATEGIES TO ADVANCE THE FIELD
Regarding clinical trials delivering genetic infor-
mation, Jacques Fellay noted the importance of 
large sample sizes, homogenous patient popula-
tions, and well-deﬁ   ned phenotypes for genetic 
association analyses. He recounted the IDEAL 
whether replication should be at the level of genes, 
gene pathways, or gene networks. She introduced 
issues regarding allelic heterogeneity and popula-
tion differences and noted that most tagging single 
nucleotide polymorphisms (SNPs) are not func-
tional. Phenotypes may reﬂ  ect combined effects of 
multiple rare variants in different individuals or 
interactions among common and/or rare variants 
in the same individual. The importance of pheno-
typing precision may depend on sample size and 
other aspects of study design.
TRANSLATING GENETIC TESTING INTO 
CLINICAL CARE
Regarding viral genetics and nongenetic factors, 
Daniel Kuritzkes reviewed the use of laboratory 
assays for CD4 cells, HIV-1 RNA, viral drug resis-
tance, and chemokine receptor tropism to inform 
HIV treatment decisions. Factors associated with 
HIV disease progression in untreated patients 
include HLA type, CCR5 genotype, and coinfec-
tions. Genomics research has enhanced under-
standing of viral-host interactions. Host genetic 
markers could potentially be used to stratify 
populations based on risk of disease progression, 
informing decisions about when to start therapy. 
He considered host and viral factors that affect 
ART response and noted the potential for genetics 
to elucidate underlying mechanisms of virus-host 
interactions during ART.
The US Food and Drug Administration’s (FDA) 
role in bringing genetic tests to clinical practice 
was discussed by Shashi Amur. Several FDA 
centers govern different aspects of antiretroviral 
drugs and monitoring: Center for Drug Evaluation 
and Research (CDER) is involved through drug 
approval and labeling; Center for Biologics Evalu-
ation and Research (CBER) approves tests for HIV 
monitoring; and Center for Devices and Radiologi-
cal Health (CDRH) approves human genetic tests. 
Genetic test information may be included in initial 
labeling or added later, with strength of evidence 
affecting strength of label wording. She empha-
sized an FDA goal of supporting development of 
genetic predictors of treatment response and toxic-
ity. The already successful incorporation of some 
genetic tests into clinical care raises optimism that 
challenges can be overcome.
Lessons from warfarin studies were recounted 
by Brian Gage, including the initial implication 
 P HARMACOGENOMICS OF HIV THERAPY ￿ HAAS ET AL  279the research question. She noted beneﬁ  ts of precise, 
objective endpoints.
Regarding the cost-effectiveness of genetic test-
ing, Kenneth Freedberg discussed implications 
of cost-effectiveness analysis applied to clinical 
trials and strategies of care. Cost-effectiveness is 
a method of understanding the value of different 
interventions in HIV, deﬁ   ning the incremental 
cost-effectiveness ratio in terms of dollars per year 
of life saved or dollars per quality-adjusted life 
year saved. He described how higher CD4 counts 
correlate with lower cost of care. In the United 
States, HLA-B*5701 testing has been shown to be 
cost-effective by helping optimize the use of ART. 
Whether genomic testing will be cost-effective 
in resource-limited settings will depend on the 
relative cost of the tests, the prevalence of genomic 
variances, and cost and availability of different 
ART regimens.
Regarding diagnostic test development, Christos 
Petropoulos provided slides describing 2 routes to 
diagnostic test approval – the Hercep test (Dako 
North America, Inc., Carpinteria, California, USA) 
and the Troﬁ  le assay (Monogram Biosciences, Inc., 
South San Francisco, California, USA). Hercep 
identiﬁ  es HER2-positive breast cancer, which can 
be treated with trastuzumab. This standard of care 
test enables prescribing, with well-aligned position-
ing of the diagnostic test by drug manufacturer and 
assay provider. The Troﬁ  le assay identiﬁ  es HIV-1 
chemokine receptor tropism and informs prescrib-
ing of CCR5 inhibitors. This test is also standard of 
care but is perceived as a barrier to prescribing. It is 
best if objectives of pharmaceutical/biotechnology 
and diagnostic companies can be aligned. Oppor-
tunities include reduced health care costs and 
expanded indications for targeted therapies.
Regarding genetics of complex traits, Teri Mano-
lio described how GWAS has accelerated progress 
in describing complex traits. She highlighted a Web 
page summarizing published genome-wide associ-
ations (www.genome.gov/gwasstudies/). Lessons 
from GWAS include surprising signals in unex-
pected genes, signals in gene “deserts” (regions 
devoid of protein-coding genes), and individual 
genes associated with multiple disparate pheno-
types. Small genetic odds ratios may reﬂ  ect con-
tributions of environmental factors. Associations 
with large effects will be hard to ﬁ  nd if   causative 
variants are rare.
study, a prospective trial of hepatitis C virus (HCV) 
therapies. Most IDEAL participants consented for 
genetic research. By GWAS, sustained virologic 
response rates were 80% and 30% among groups 
with favorable and unfavorable IL28B alleles, 
respectively.23 Allele frequencies largely explain 
racial disparities in HCV treatment response. This 
GWAS already shapes how HCV treatment and 
drug development is considered, but it was only 
possible because consent for genomic research was 
requested in IDEAL. He emphasized that every 
clinical trial should include genetic consent and 
DNA collection for future analyses.
Challenges in prospectively testing genetic 
markers through clinical trials were described 
by Elizabeth Phillips. The history of HLA-B*5701 
screening for abacavir spanned 6 years from 
discovery to clinical practice. The prospective, 
randomized PREDICT-1 study deﬁ  nitively estab-
lished the value of HLA-B*5701 testing among 
Caucasians and showed the importance of an 
intermediate phenotype (abacavir skin patch test-
ing) to deﬁ   ne true immunologically mediated 
abacavir hypersensitivity.6 The retrospective, case-
control SHAPE study replicated this association 
in patients of African descent.5 Many immune-
mediated drug reactions will involve HLA, but 
the combination of such a strong association for 
a problem as prevalent as abacavir hypersensitiv-
ity is unlikely for most drugs. The abacavir story 
exemplified the importance of various study 
designs, intermediate phenotypes, and valida-
tion and ongoing quality assurance of laboratory 
technologies.
Prospective clinical trial designs relevant to 
pharmacogenomics were discussed by Heather 
Ribaudo. Clinical trials provide more robust causal 
evidence than observational studies. With targeted 
prospective designs, individuals of known geno-
type may be prospectively studied speciﬁ  cally to 
collect information on phenotypes likely affected 
by genetics. With restrictive/enrichment designs, 
genetic screening enriches the study population 
for genotypes of interest and then randomizes 
participants to an intervention. These designs may 
require relatively few participants to address tar-
geted questions. She described beneﬁ  ts of a large, 
phase 3 strategy design in which all potential drug 
recipients are randomized to genetic screening or 
not (eg, PREDICT-16). Optimal design depends on 
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Issues that may cause concern for IRBs include 
indeﬁ  nite duration of DNA storage and unlimited 
scope of analyses. At least some non-US ECs may 
insist upon narrowly deﬁ  ned scopes of analyses 
and may be reluctant to allow DNA or genetic data 
to leave their countries.
Recommendation 2: Create a Web-based cata-
logue of HIV clinical trials and cohorts suitable 
for genetic analyses. A barrier to progress in HIV 
pharmacogenomics is lack of readily available 
information regarding existing trial and cohort 
datasets with broad consent and available DNA. 
Many genomic analyses occur only following 
chance interactions between genomic investiga-
tors and individuals familiar with particular trials 
or cohorts. Cataloguing such information would 
facilitate genetic discovery and replication. A Web-
based listing of such studies, including selected 
available phenotypes, need not be expensive and 
would include both federally funded and non-
federal studies. Individuals familiar with each 
study would contribute a minimal amount of infor-
mation. Non-US investigators should be involved 
from the outset. To provide incentive for data 
uploads, one suggestion was to limit catalogue 
queries to individuals who have uploaded data. 
Web sites already exist that compile information 
about various aspects of clinical trials and/or phar-
macogenomics (eg, ClinicalTrials.gov, PharmGKB, 
HIV-Pharmacogenomics.org). One option would 
be to grow the catalogue from an existing site.
Recommendation 3: Establish an international 
HIV pharmacogenomics consortium. Investi-
gators worldwide have interests and expertise 
directly relevant to HIV pharmacogenomics, but 
work in relative isolation. This is problematic, as 
many individual datasets are inadequately pow-
ered to identify and/or replicate associations. In 
RECOMMENDATIONS FROM WORKSHOP 
PARTICIPANTS
Working groups generated speciﬁ  c recommen-
dations. Major recommendations are listed in 
Table 2.
Recommendation 1: Every HIV-related clini-
cal trial should offer participants the opportu-
nity to consent for future genetic analyses, with 
prolonged DNA storage and broad scopes of 
 analyses. At the time of clinical trial performance, 
all future genomic questions cannot be anticipated. 
Every HIV-related clinical trial should therefore 
store DNA for future analysis. Consent should 
encompass the broadest possible scope of genomic 
assays and clinical phenotypes. In addition, DNA 
storage should be without time limit, because 
important genomic questions may arise decades 
after trial completion.
Some attendees favored a federal mandate that 
all clinical trials bank DNA and that consent for 
genetic analyses be required for participation in 
any trial. The prevailing sentiment among attend-
ees, however, was that these approaches would be 
prohibited by legal, conﬁ  dentiality, and other con-
cerns. An alternative is to require that participants 
have the opportunity to consent “yes” or “no” for 
future genetic analyses, without their response 
affecting trial eligibility. The institutional review 
board (IRB) for at least one US academic center 
requires that every protocol offers participants 
such an opportunity unless the investigator justi-
ﬁ  es otherwise. Mandating such wording nation-
ally, however, could complicate trials enrollment 
and affect public sentiment about research. In some 
situations, “opt-out” consenting may be feasible, in 
which genetic research is allowed unless the par-
ticipant proactively declines.24
Ethics committees (ECs) and IRBs ultimately 
decide what is allowed. In the United States, IRB 
1. Every HIV-related clinical trial should offer participants the opportunity to consent for future genetic 
analyses, with prolonged DNA storage and broad scopes of analyses.
2. Create a Web-based catalogue of HIV clinical trials and cohorts suitable for genetic analyses.
3. Establish an international HIV pharmacogenomics consortium.
4. Disseminate information regarding HIV pharmacogenomic research widely and effectively.
5. Support database, statistical, and computational genomics infrastructures needed for successful HIV 
pharmacogenomics.
Table 2.  Major recommendations from workshop participants
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support for all the personnel with complementary 
expertise needed for these activities. Of note, the 
preparation of such datasets can be tedious and 
time-consuming and may not be recognized for 
academic advancement.
ADDITIONAL POINTS OF DISCUSSION
Workshop participants emphasized a number 
of other points as follows. (1) To deﬁ  ne genotype-
phenotype associations, various study designs 
should be pursued in parallel, not sequentially (eg, 
observational and prospective studies, studies of 
clinical outcomes and intermediate phenotypes, 
studies in different populations and contexts, etc). 
(2) When observational evidence of genetic asso-
ciation is sufﬁ  ciently strong, prospective clinical 
trials to test genetic predictors may not be required. 
However, treatment guidelines are most strongly 
affected by prospective trials, and information in 
different populations is required to deﬁ  ne gener-
alizability. (3) Cost-effectiveness modeling plays 
an important role in assessing genetic markers 
and the feasibility of application to clinical prac-
tice. (4) Both positive and negative ﬁ  ndings from 
genetic association studies should be presented. 
(5) Genetic studies should consider nongenetic 
and ecological factors (eg, nutritional status, 
medication adherence, concomitant medications, 
and concomitant illnesses). (6) The most relevant 
phenotypes should be carefully chosen based on 
clinical impact. Considerations include drugs that 
are widely used, and populations in which they 
are prescribed. (7) Identifying genetic predictors 
of adverse events is most critical, but predictors of 
virologic response would also be of considerable 
interest. (8) Pharmacogenomics studies should 
incorporate pharmacokinetic analyses. Pharmaco-
kinetic data enhance interpretation of genetic asso-
ciation studies, and predictors of drug disposition 
could inform dosing schedules. (9) Pharmacoge-
nomics research beneﬁ  ts from an understanding of 
pharmacokinetic-pharmacodynamic relationships. 
(10) As much information as possible should be 
gleaned from extant data and specimens through 
association analyses, cost-effectiveness analyses, 
and value-of-information analyses. (11) Merging 
data from various clinical trials and cohorts would 
be facilitated if studies routinely and uniformly col-
lected minimum sets of key variables. (12) Results, 
addition, because genotype-phenotype associa-
tions may vary depending on genetic and environ-
mental factors, associations must be studied in 
different populations and contexts worldwide. 
The number and diversity of potential pharma-
cogenomic questions require involvement of 
many investigators. An international consortium 
of investigators could work together to identify 
the most important HIV pharmacogenomic ques-
tions, develop phenotype precision and consensus, 
combine datasets to address questions beyond the 
scope of individual groups or datasets, and lever-
age resources to efﬁ  ciently complete analyses. Such 
a consortium could also enhance communication 
among HIV pharmacogenomic investigators.
Recommendation 4: Disseminate informa-
tion regarding HIV pharmacogenomic research 
widely and effectively. Pharmacogenomics inves-
tigators are understandably enthusiastic about the 
potential beneﬁ  ts of their work, given the precedent 
of a genetic screening test that already improves 
HIV drug safety and reduces cost (ie, HLA-B*5701 
for abacavir hypersensitivity6). Other groups, how-
ever, may not share this enthusiasm, perhaps due 
to concern that genetic information may personally 
identify patients, that incorporating genomics into 
clinical care will increase complexity or cost, or that 
beneﬁ  ts may not reach populations or countries in 
which discoveries are made. To engage partners in 
this endeavor, information regarding beneﬁ  ts and 
challenges of pharmacogenomic research must be 
effectively shared with persons living with HIV, 
providers, researchers, policymakers, and the gen-
eral public worldwide. The consortium mentioned 
in Recommendation 3 could play a role in dissemi-
nating information.
Recommendation 5: Support database, statisti-
cal, and computational genomics infrastructures 
needed for successful HIV pharmacogenomics. 
Essential for progress in HIV pharmacogenomics 
research are robust clinical trial and cohort datasets 
to merge with genomic data. An underappreci-
ated aspect of this work is the need for personnel 
with the skills and time for this task. Even with 
prospective trials and cohorts, considerable data 
processing may be required to generate clean, well-
documented datasets for speciﬁ  c questions. Such 
work requires individuals who understand subtle-
ties of study design, performance, and data col-
lection. For complex datasets with many possible 
phenotypes of interest, judgment may be needed 
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(13) A potential application of pharmacogenomics 
in resource-limited countries is to predict whether 
drugs are likely to be safe for their population. 
For example, if a reliable genetic predictor of drug 
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predictor. (14) Although most genetic markers may 
not reach clinical application, much may be learned 
from genetic studies that elucidate underlying 
mechanisms of disease pathogenesis.
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